21:51:29 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2022-12-15 12:50:41
Moss, 15 December 2022

Reference is made to the annual general meeting 18 May 2022 where a statement of
remuneration to key personnel was given. In accordance with this statement the
board of Gentian Diagnostics ASA has allocated a total of 219,996 options to key
employees under the existing option program.

The following number of options have been allocated to primary insiders of
Gentian Diagnostics ASA:

Hilja Ibert, Chief Executive Officer: 80,000 options. Following the allocations
Ms. Ibert holds 6,525 shares and 359,924 options

Njaal Kind, Group Chief Financial Officer: 19,996 options. Following the
allocations Mr. Kind holds 21,125 shares and 175,666 options in the Company.

Torsten Knüttel, Vice President R&D: 10,000 options. Following the allocation
Mr. Knüttel holds 1,125 shares and 40,000 options in the Company.

Jack Andreassen, Vice President Business Development: 10,000 options. Following
the allocation Mr. Andreassen hold 4,385 shares and 32,500 options in the
Company.

Markus Jaquemar, Vice President Sales and Marketing: 25,000 options. Following
the allocation Mr. Jaquemar holds 47,500 options in the Company.

The exercise price for the options granted is NOK 46,67 being the average
volume-weighted share price on the Oslo Stock Exchange from 1 January 2022 to 13
December 2022. The right to exercise the options is vested over a period of 2
years, with 50% of the options vesting by the end of each year as follows: (i)
50% of the options granted, no earlier than 3 years after the allocation date
(ii) 50% of the options granted, no earlier than 4 years after the allocation
date.

Attached are the notifications of the transactions pursuant to the market abuse
regulation article 19.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

For further information, please contact:

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525